GlassScriptPhysician profile
Jeffrey A Green
NPI 1366415804
$15,150.50
in general payments reported to CMS, 2019-2025
37 companies · $2,698 in 2025
The $2,698 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $1,838 · 2021: $2,250 · 2022: $2,290 · 2023: $1,972 · 2024: $2,431 · 2025: $2,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,100.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,502.11 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,470.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,334.37 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,089.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $992.14 | 2021-2025 | Verquvo, Lagevrio, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $923.20 | 2019-2025 | Farxiga, Wainua, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $916.47 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $915.00 | 2019-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $863.41 | 2019-2025 | Onpattro, Amvuttra |
| Amarin Pharma, INC. | $792.44 | 2019-2023 | |
| Esperion Therapeutics, INC. | $668.59 | 2020-2025 | Nexletol |
| Biotronik INC. | $521.89 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $503.18 | 2019-2022 | |
| Novo Nordisk INC | $483.87 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $230.96 | 2020-2024 | Cardiomems |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $217.67 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $215.71 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $210.99 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $201.41 | 2019-2025 | Evkeeza |
| Scpharmaceuticals INC. | $190.00 | 2024-2025 | |
| Irhythm Technologies, INC. | $152.57 | 2021-2022 | |
| Bridgebio Pharma, INC. | $119.90 | 2025 | Attruby |
| Biosense Webster, INC. | $117.37 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $105.54 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $47.24 | 2025 | |
| Abiomed | $45.79 | 2024 | Impella |
| Baxter Healthcare | $38.06 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.66 | 2023 | Lifevest |
| Portola Pharmaceuticals, LLC | $36.97 | 2019-2020 | |
| Medicomp INC | $34.44 | 2024 | Telepatch Cardiac Monitor |
| Medtronic, INC. | $31.99 | 2024 | Corevalve Evolut R |
| Preventice Services, LLC | $30.14 | 2019-2020 | |
| Lilly USA, LLC | $26.26 | 2025 | Zepbound |
| Philips North America LLC | $23.81 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Mannkind Corporation | $22.52 | 2025 | |
| Boston Scientific Corporation | $20.60 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Medtronic Vascular, INC. | $16.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.